The Superiority of Zoledronic Acid Over Risedronate for Paget's Disease: A 16-Year Experience at a Single Institution.
bone
paget’s disease
risedronate
treatment
zoledronic acid
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
25
12
2022
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Introduction Bisphosphonates are considered to be the treatment of choice for patients with active Paget's disease. The aim of this study was to record and assess the therapeutic effect in response to a single intravenous infusion of 5mg zoledronic acid or oral risedronate. Methods A retrospective observational study was conducted of 89 patients in Greek patients with active Paget's disease from a tertiary hospital in North Greece. Patients were treated with either a single intravenous infusion of 5mg zoledronic acid (1st group, n=46) or 30mg of risedronate per day for 60 days (2nd group, n=43). All patients received 1000mg of calcium and 400-800IU of calciferol daily. The primary outcome measure was to record the therapeutic response defined as the control of patients' symptoms and normalization of the biochemical markers of bone metabolism. The secondary outcome measures included the patient's quality of life which was evaluated by the questionnaire SF-36 and adverse events. Results Forty patients from the zoledronic acid group and 38 patients from the risedronate group, who reported pain at the beginning of the study, showed a significant degree of clinical improvement. All the patients in our study showed a therapeutic response at six months while the remission was persistent at 36 months. There was a statistically significant difference between pre-treatment basal results and values at the sixth and 36th months of treatment (p<0.001) between the two groups. Conclusion The study demonstrated the superiority of zoledronic acid over risedronate in patients with active Paget's disease.
Identifiants
pubmed: 36712714
doi: 10.7759/cureus.32923
pmc: PMC9873448
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e32923Informations de copyright
Copyright © 2022, Zidrou et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Endocr Pract. 2015 Oct;21(10):1111-6
pubmed: 26151420
Mayo Clin Proc. 2008 Sep;83(9):1032-45
pubmed: 18775204
Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):117-121
pubmed: 31016165
J Bone Miner Metab. 2008;26(6):635-41
pubmed: 18979164
J Clin Endocrinol Metab. 2014 Dec;99(12):4408-22
pubmed: 25406796
Am J Med. 1999 May;106(5):513-20
pubmed: 10335722
Orthop Clin North Am. 2015 Oct;46(4):577-85
pubmed: 26410646
Osteoporos Int. 2014 Sep;25(9):2221-3
pubmed: 24899102
N Engl J Med. 2005 Sep 1;353(9):898-908
pubmed: 16135834
Nat Clin Pract Rheumatol. 2006 Apr;2(4):186-7
pubmed: 16932682
J Bone Miner Res. 2007 Jan;22(1):142-8
pubmed: 17032148
J Bone Miner Res. 1999 Oct;14 Suppl 2:66-9
pubmed: 10510216
Lancet. 2008 Jul 12;372(9633):155-163
pubmed: 18620951
J Bone Miner Res. 2006 Dec;21 Suppl 2:P3-8
pubmed: 17229005
Metabolism. 2018 Mar;80:5-14
pubmed: 28780255
J Bone Miner Res. 2011 Sep;26(9):2261-70
pubmed: 21638319